GlobeNewswire Inc.··NaPrelude Therapeutics' KAT6A Degrader Shows Complete Tumor Regressions in Breast Cancer Models
Prelude Therapeutics shows complete tumor regressions with PRT13722, a first-in-class oral KAT6A degrader, planning IND filing mid-2026 and clinical trials by year-end.
PRLDprecision oncologyHR+/HER2- breast cancer